These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32815828)

  • 1. Sertoli-Leydig Cell Tumors of the Ovary With Follicular Differentiation Often Resembling Juvenile Granulosa Cell Tumor: A Report of 38 Cases Including Comments on Sex Cord-Stromal Tumors of Mixed Forms (So-called Gynandroblastoma).
    Ordulu Z; Young RH
    Am J Surg Pathol; 2021 Jan; 45(1):59-67. PubMed ID: 32815828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gynandroblastoma With Juvenile Granulosa Cell Tumor and Concurrent Renal Cell Carcinoma: A Case Report and Review of Literature.
    Wilberger A; Yang B
    Int J Surg Pathol; 2015 Aug; 23(5):393-8. PubMed ID: 26169919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.
    Young RH
    Mod Pathol; 2005 Feb; 18 Suppl 2():S81-98. PubMed ID: 15502809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian sex cord-stromal tumours and their mimics.
    Young RH
    Pathology; 2018 Jan; 50(1):5-15. PubMed ID: 29132723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary.
    Rishi M; Howard LN; Bratthauer GL; Tavassoli FA
    Am J Surg Pathol; 1997 May; 21(5):583-9. PubMed ID: 9158684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
    Kato N; Uchigasaki S; Fukase M; Kurose A
    Int J Gynecol Pathol; 2016 Jan; 35(1):41-7. PubMed ID: 26166720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed sex cord-stromal tumor (gynandroblastoma) with malignant morphology involving both ovaries: a case report.
    Maraqa B; Al-Ashhab M; Kamal N; Sughayer M; Barakat F
    J Int Med Res; 2023 Jul; 51(7):3000605231187796. PubMed ID: 37493465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 14-3-3 sigma is a useful immunohistochemical marker for diagnosing ovarian granulosa cell tumors and steroid cell tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2013 Mar; 32(2):156-62. PubMed ID: 23370648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Schultz KAP; Harris AK; Finch M; Dehner LP; Brown JB; Gershenson DM; Young RH; Field A; Yu W; Turner J; Cost NG; Schneider DT; Stewart DR; Frazier AL; Messinger Y; Hill DA
    Gynecol Oncol; 2017 Dec; 147(3):521-527. PubMed ID: 29037807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ovarian tumors with endocrine function].
    Guo LN; Liu TH; Sun AJ; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):217-20. PubMed ID: 15256111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sex cord-stromal tumors of the ovary : Current aspects with a focus on granulosa cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas].
    Kommoss F; Lehr HA
    Pathologe; 2019 Feb; 40(1):61-72. PubMed ID: 30659330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerosis in Sex Cord-Stromal Tumors Other Than the Sclerosing Stromal Tumor: A Report of 70 Cases.
    Devins KM; Young RH
    Am J Surg Pathol; 2023 Jul; 47(7):774-784. PubMed ID: 37184091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunohistochemical analysis of granulosa and sertoli components in ovarian sex cord-stromal tumors with mixed differentiation: potential implications for derivation of sertoli differentiation in ovarian tumors.
    Vang R; Herrmann ME; Tavassoli FA
    Int J Gynecol Pathol; 2004 Apr; 23(2):151-61. PubMed ID: 15084844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex steroid biosynthesis enzymes in ovarian sex-cord stromal tumors.
    Costa MJ; Morris R; Sasano H
    Int J Gynecol Pathol; 1994 Apr; 13(2):109-19. PubMed ID: 8005731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histogenetic consideration of ovarian sex cord-stromal tumors analyzed by expression pattern of cytokeratins, vimentin, and laminin. Correlation studies with human gonads.
    Park SH; Kim I
    Pathol Res Pract; 1994 May; 190(5):449-56. PubMed ID: 7527534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors).
    McCluggage WG; Young RH
    Am J Surg Pathol; 2007 Apr; 31(4):592-7. PubMed ID: 17414107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertoli-Leydig cell tumor: a clinicopathological analysis in a comprehensive, national cohort.
    Bekker P; Miland-Samuelsen AR; Smerdel MP; Schnack TH; Lauszus FF; Karstensen SH
    Int J Gynecol Cancer; 2023 Dec; 33(12):1921-1927. PubMed ID: 37907261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testicular Neoplasms With Sex Cord and Stromal Components Harbor a Recurrent Pattern of Chromosomal Gains.
    Acosta AM; Sholl LM; Maclean F; Kao CS; Ulbright TM
    Mod Pathol; 2024 Jan; 37(1):100368. PubMed ID: 37871653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging in gynecological disease (27): clinical and ultrasound characteristics of recurrent ovarian stromal cell tumors.
    Moro F; Giudice MT; Bolomini G; Moruzzi MC; Mascilini F; Quagliozzi L; Ciccarone F; Scambia G; Fagotti A; Valentin L; Testa AC
    Ultrasound Obstet Gynecol; 2024 Mar; 63(3):399-407. PubMed ID: 37774092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unclassified ovarian gonadal stromal tumors. A clinicopathologic study of 32 cases.
    Seidman JD
    Am J Surg Pathol; 1996 Jun; 20(6):699-706. PubMed ID: 8651349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.